What's this about ? OTTAWA, ONTARIO--(Marketwired - Aug 26, 2016) - PhytoPain Pharma Inc. ("PhytoPain Pharma" or "PPP"), a subsidiary of GrowPros Cannabis Ventures Inc. ("GrowPros" or the "Company") (CSE:GCI), is pleased to announce the creation of its Scientific and Clinical Advisory Board. The board is comprised of experts in clinical research, pain management as well as cancer and neurological product drug development. The Advisory Board will provide strategic guidance on PPP's clinical development program, clinical trial designs, and pipeline of preclinical and clinical candidates for the treatment of pain, insomnia and other conditions affecting cancer patients. "This team of accomplished scientific and clinical experts will collaborate with us on our goal of bringing these new prescription drug products to patients while addressing the concerns of the medical establishment and regulators," stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs.
The President of the board will report directly to the Board of Directors of GCI. The advisory board is expected to meet before the end of October to review the clinical development plan of PPP's phase I clinical study of smoked cannabis and the development of future cannabis-based therapeutics. PPP intends on submitting the Clinical Trial Application (CTA) after incorporating the recommendations obtained from its expert advisory panel into the clinical development program. PPP also intends on submitting the clinical protocol to the US Food & Drug Administration (FDA) for review. PPP is developing this prescription drug product for both the Canadian and USA market and intends on obtaining approval from Health Canada and the US FDA.
"We are honored to have these distinguished experts join GCI's new advisory board," said Ryan Brown CEO of GCI. "We are enlisting these experts to assist PPP in developing prescription drugs for patients suffering from uncontrolled pain."
The President of the Advisory Board is Dr. Luc Vachon, Ph.D. Dr. Vachon has more than 25 years of experience in drug development. He has worked in two multinational pharmaceutical organizations, a CRO, and two "biotech" companies. He has held various positions, including Global Product Team Leader, Executive V.-P. of R&D, CEO and president, and has also been teaching in the academia. He is presently active as independent consultant in drug development.
Dr. Andr Blanger, MD is a member of the pain clinic at the Htel-Dieu de Lvis and at Clinique Mdicale Valcartier. He is a recognized medical expert in pain management and provides continuing education on pain management for multiple provincial and national programs.
Dr. Gordon D. Ko MD, CCFP(EM), FCFP, FRCPC www.DrKoPRP.com is a specialist in Physical Medicine and Rehabilitation (Physiatry) with subspecialty in Pain Medicine. He is a former Senior University Associate Professor and current Medical Director, Interventional Physiatry clinics and Adjunct Lecturer at Sunnybrook Health Sciences Centre, University of Toronto and the Canadian Centre for Integrative Medicine (Markham). His expertise with Platelet-rich Plasma (PRP) for Back Pain and Botox injections for Osteoarthritis made headline CTV national news. With over 25 years' experience in treating Fibromyalgia(FMS) and chronic neuropathic pain (including Cannabinoids, Functional Medicine), he was selected on the Canadian Pain Society committee that developed new guidelines (2012) for FMS management. More recently, he was lead author for a peer-reviewed review paper (J Pain Research 2016) on Medical Cannabis: a Canadian Perspective.
Dr. Pierre Arsenault, Ph.D., M.D., CPI is a family medicine practitioner and pain management expert and is an associate professor of family medicine at Universit de Sherbrooke. He has a vast experience in clinical research and is a Clinical Physician Investigator (CPI) at DIEX Research